Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-10

Study Completion Date

2024-02-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the efficacy of SynPath™, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment.

Half the subjects with be treated using SynPath™ while the other half will receive Standard of Care treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Controlled Clinical Investigation Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot Ulcers

NCT05519501

Diabetic Foot Ulcer

COMPLETED NA

Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers

NCT06028386

Non-healing Wound Diabetic Foot Ulcer

UNKNOWN NA

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426

Diabetic Foot Ulcer Foot

COMPLETED NA

Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

NCT00387101

Diabetic Foot Ulcer

TERMINATED PHASE3

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

NCT02427802

Foot Ulcer, Diabetic Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One hundred and thirty-eight (138) subjects with chronic Diabetic Foot Ulcers ranging in size from 1cm2 to 25cm2 will be randomized 1:1 to either SynPath™ or Standard of Care after the completion of a 14 day screening/run-in period. Following the of run-in period the subjects with a 'hard to heal' or chronic, (\>4 weeks) nonresponsive Wagner Grade 1 or 2 diabetic foot ulcer will be randomized to receive either SynPath™ or SOC treatment. Both treatment groups will require subjects to use off-loading device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Chronic Foot Ulcer Wound Healing Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NovoSorb SynPath

Arm receives application on NovoSorb SynPath Dermal Matrix and appropriate Off-loading

Group Type EXPERIMENTAL

SynPath Acellular Dermal Matrix plus Off-loading Device

Intervention Type DEVICE

Application of SynPath

Standard of Care

Arm receives application of wound dressing composed of 90% Collagen and 10% Alginate plus appropriate Off-loading

Group Type ACTIVE_COMPARATOR

Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device

Intervention Type DEVICE

Application Wound Dressing composed of Collagen and Alginate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SynPath Acellular Dermal Matrix plus Off-loading Device

Application of SynPath

Intervention Type DEVICE

Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device

Application Wound Dressing composed of Collagen and Alginate

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female ≥ 18 years
2. A signed and dated informed consent form has been obtained from the subject
3. Confirmed Type 1 or 2 diabetes with a hemoglobin HbA1c ≤12% within 90 days of informed consent
4. Current reference ulcer has been in existence for longer than four (4) weeks with confirmed failure of a prior treatment to heal the ulcer, prior to signing informed consent for trial participation. Verbal statement from prior treating clinician or patient can be used as confirmation of treatment failure.
5. Reference ulcer has been diagnosed as either a partial or full thickness diabetic foot ulcer without tunneling, undermining, sinus tracts or /exposed bone, with a scale rating of a Wagner Grade 1 or Wagner Grade 2 extended to ligament, tendon, and joint capsule with no bone exposure
6. Ulcer is either located on the foot or ankle with at least 50% of ulcer below medial aspect of the malleolus
7. Ulcer size (area) ≥1cm² and ≤25cm² post-debridement at both screening visit 1 and at baseline/randomization visit 3
8. There is a minimum 1cm margin between the qualifying reference study ulcer and any other ulcers on the specified foot, post debridement
9. Subject has adequate vascular perfusion of the affected limb, as defined by at least one of the following:

1. Ankle-brachial Index (ABI) ≥ 0.65 or ≤1.2
2. Toe pressure (plethysmography) \>50mmHg
3. TcPO2 \>40mmHg
4. Or as an alternative, the arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable.
10. Subject or responsible caregiver is willing and able to adhere to schedule of required applicable dressing changes as well as off-loading for the location of the reference ulcer
11. Subject is able and willing to comply with study procedures
12. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence) during the course of the study and undergo pregnancy tests.
13. A two-(2) week run-in period will Standard of Care treatment plus required offloading precede randomization in the trial to document the indolent nature of the subject's selected selected. The subject may be randomized if the reference ulcer has not reduced in area \>30% from screening visit 1 to baseline/randomization visit 3.

Exclusion Criteria

1. Subject was previously randomized and treated under this clinical study protocol
2. Subject has suspected or confirmed signs/symptoms of gangrene or wound infection as evidenced by redness, pain, and purulent drainage on any part of the index limb as confirmed by X-ray or biopsy
3. Subject has a history of hypersensitivity to polyurethane, as determined by prior medical history
4. Subject has participated in another clinical trial involving a device or a systemically administered investigational study drug/treatment within 30 days of randomization
5. Subject has received, or is scheduled to receive a medication or treatment which is known to interfere with or affect the rate or quality of wound healing within 30 days of signing the informed consent form
6. Subject has a history of bone cancer or metastatic disease on the index limb, radiation therapy to the foot, or has had chemotherapy within twelve (12) months prior to signing informed consent form for trial participation
7. Reference ulcer, in the clinical opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
8. Subject has a condition that would interfere with their ability to adhere with the treatment regimen or has a known history of poor adherence with medical treatment
9. In the opinion of the Investigator, the subject has a history of or is currently diagnosed with any illnesses or conditions, other than diabetes, that could interfere with wound healing such as auto-immune disorders, end-stage renal disease, severe malnutrition, liver disease or connective tissue disorders
10. In the clinical opinion of the Investigator, the subject has an active or unstable Charcot foot
11. Subject has ulcers secondary to a disease other than diabetes (e.g., vasculitis, neoplasms, or hematological disorders)
12. In the clinical opinion of the Investigator, the subject has excessive lymphoedema that could interfere with off-loading and/or wound healing
13. Subject with an active infection at the reference ulcer
14. Subject has a non-healed surgical site from a prior amputation located in the index limb that has been open for less than 30 days
15. Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes within 30 days of randomization or is scheduled to receive treatment during the study
16. Subject has been treated with hyperbaric oxygen or topical oxygen therapy within five (5) days of the Screening Visit or is scheduled to receive hyperbaric oxygen treatment or topical oxygen therapy during the study
17. Subject has been treated with Negative Pressure Wound Therapy (NPWT) within 72 hours of the Screening Visit
18. Subject receiving dialysis treatment: hemodialysis or peritoneal dialysis
19. Subject has received an organ transplant
20. Subjects with a history of more than two (2) weeks treatment with immunosuppressants including prednisone 10 mg daily or an equivalent dose of other oral steroids, or application of topical steroids to the ulcer surface within one (1) month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
21. Active osteomyelitis or bone infection of the index foot. A subject may be enrolled in study if the subject:

1. is at least 8 weeks post osteomyelitis diagnosis
2. has been treated appropriately
3. has only intact joint capsule exposed with no bone exposure
22. Subjects presenting with an ulcer probing to bone (Wagner Grade 3)
23. Subject is currently pregnant or actively trying to conceive.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No